Get the Stockscreener App
28.29
1.91%
0.53
Faeth Therapeutics Inc stock is traded at $28.29, with a volume of 129.15K.
It is up +1.91% in the last 24 hours and up +15.28% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$27.76
Open:
$27.16
24h Volume:
129.15K
Relative Volume:
1.60
Market Cap:
$729.28M
Revenue:
-
Net Income/Loss:
$-184.46M
P/E Ratio:
-0.1982
EPS:
-142.7277
Net Cash Flow:
$-24.11M
1W Performance:
+9.35%
1M Performance:
+15.28%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$27.03
$28.29
1-Week Range:
$25.80
$29.40
52-Week Range:
$17.50
$37.90
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
28.29 | 729.28M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Faeth Therapeutics Inc Stock (FTH) Latest News
Faeth Therapeutics Adopts Performance-Based Stock Option Plan - TipRanks
Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver - TradingView
Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options - Stock Titan
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
Citizens initiates Faeth Therapeutics stock at outperform, $51 target By Investing.com - Investing.com Canada
Citi Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FTH Reiterated by BTIG -- Price Target Maintained at $55 - GuruFocus
Issuance/retirement of debt (net) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc trading resumes - TipRanks
A Closer Look At Faeth Therapeutics' PIKTOR - RTTNews
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Faeth’s PIKTOR Trial Targets Advanced Breast Cancer With a New Combo Approach - TipRanks
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com UK
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
Enterprise value to EBITDA forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Sahm
Price to earnings forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics Inc Stock (FTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Faeth Therapeutics Inc Stock (FTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
| Peyer James | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):